1Y Close · As of Aug 26, 2026
HUMASIS operates in the Pharmaceuticals sector.
Legal name: HUMASIS CO., LTD.
In fiscal year 2025, HUMASIS (205470) reported revenue of 30.1 billion KRW, up 18.5% from 25.4 billion KRW a year earlier.
Operating profit was -10.6 billion KRW and net income was -21.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 73.4 billion KRW, with a P/B of 0.31.
These figures can be verified in the DART filing (receipt no. 20260323001233).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 30.1B | -10.6B | -21.7B |
| 2024 | 25.4B | -10.6B | -35.6B |
| 2023 | 13.8B | -52.4B | -55.4B |
Recent Filings
Large Shareholding Report (General)
Officer/Major Shareholder Ownership Report
Record Date Setting
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 1 cancellation(s).
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-24 | Large Shareholding Report (General) |
| 2026-08-24 | Officer/Major Shareholder Ownership Report |
| 2026-08-14 | Record Date Setting |
| 2026-08-14 | Meeting Resolution (Extraordinary Meeting) |
| 2026-08-14 | Large Shareholding Report (General) |